A dual effect for reducing fracture risk1-4

resorption formation
NICE and NOGG/ROS

EVENITY® is recommended by NICE and NOGG/ROS for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture5,6

NICE, National institute for Health and Care Excellence; NOGG, National Osteoporosis Guidelines Group.

View the NICE / NOGG Recommendations

NICE and NOGG recommendations

NICE 2022 recommendation5

EVENITY is recommended as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if:

  • They have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture)
AND
  • The company provides EVENITY according to the commercial arrangement

NOGG/ROS Advisory statement on the prioritisation of romosozumab in clinical practice6

Referral for, and consideration of treatment with EVENITY, is prioritised in postmenopausal women who have had a MOF within 24 months, with any one of the following:

  • A BMD T-Score ≤-3.5 (at the hip or spine)
OR
  • A BMD T-score ≤-2.5 (at the hip or spine
AND EITHER
  • Vertebral fractures (either a vertebral fracture within 24 months or a history of ≥2 osteoporotic vertebral fractures)
OR
  • Very high fracture risk (e.g., as quantified by FRAX)

Following the approved duration of treatment with EVENITY (12 months), treatment with alendronate, zoledronate or denosumab should be initiated without delay.

Discover EVENITY clinical cases based on NOGG/ROS recommandations
patients_image

 

Examples of clinical cases of patients who are suitable for treatment with EVENITY based on the new NOGG/ROS consensus advisory statement,6 in line with NICE updated recommandations for EVENITY.5

Patient images are not based on real individuals and are for illustrative purposes only.

Meet our EVENITY patients
Prescribe EVENITY® first after a fragility fracture in postmenopausal women with severe osteoporosis1
dual arrow

The first dual-effect, bone-forming biologic

for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture1

*Differences in BMD cannot be related to reductions in the risk of fractures.

superior graph

Superior fracture risk reduction

when used for 12 months followed by alendronate vs alendronate alone:

 

  • 8.0% vs 4.1% for new vertebral fractures at 24 months (p<0.001)1,7

  • 13.0% vs 9.7% for clinical fracture (p<0.001), 10.6% vs 8.7% for non-vertebral fracture (p=0.04), and 3.2% vs 2.0% for hip fracture (p=0.02) at primary analysis (median 33 months)1,7

 

rapid arrow

Rapid and superior improvement in BMD

vs alendronate1,7 and teriparatide8 in just 12 months*

View EVENITY efficacy
2-Injections, once-a-month, for 12 months
self administered at home

 

EVENITY provides rapid and superior improvements in BMD1,7 vs alendronate with once-monthly,1 home-delivered dosing, so your patients can continue their treatment without having to leave the house.

contact_rep

Would you like to discuss EVENITY directly with a member of our UCB field team?

Request contact

EVENITY is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture1

EVENITY is contraindicated in patients with hypersensitivity, hypocalcaemia and history of myocardial infarction or stroke.1

 

One fragility fracture may lead to another9

1in3Patients

A previous fragility fracture increases
the imminent risk of a subsequent fracture10

chart
enlarge
From inspiration to innovation

What’s behind EVENITY

From the frontiers of space to the front line of fracture treatment. Watch our short film to discover exactly how EVENITY became reality.

View References
 
  1. EVENITY SmPC.
  2. Cosman F, et al. N Engl J Med 2016;37S:S132-1S43.
  3. Rosen CJ. N Engl J Med 2017:37:71479-1480.
  4. Ferrari SL. Nat Rev Rheumatol 2018;14:128.
  5. NICE. NICE Technology Appraisal Guidance — Romosozumab for treating severe osteoporosis. TA791. 25 May 2022. Available at:
    https://www.nice.org.uk/guidance/TA791. Accessed December 2022.
  6. NOGG. Consensus Advisory Statement from the National Osteoporosis Guideline Group (NOGG) and Royal Osteoporosis Society (ROS) on the use of romosozumab, following the 2022 NICE Appraisal. 30 May 2022. Available at:
    https://strwebprdmedia.blob.core.windows.net/media/Oh3jlogS/nogg-ros-romosozumab-statement-may-2022.pdf. Accessed December 2022.
  7. Saag K, et al. N Eng J Med 2017;377:1417-1427.
  8. Langdahl BL, et al. Lancet 2017;390:1585-1594.
  9. Toth E, et al. Osteoporos Int 2018 Apr;29(Suppl 1):149-565.
  10. Van Geel TA, et al. Ann Rheum Dis 2009:68:99-102.